Finance

Beta
Lists
KLBF:IDX
Kalbe Farma Tbk PT
IDR 695.00
-3.47%
(-25.00) 1D
Jun 5, 4:11:05 PM GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KLBF...
Open
IDR 705
High
IDR 710
Low
IDR 690
Mkt. cap
32.54T
Avg. vol.
66.07M
Volume
53.01M
Dividend
2.88%
Quarterly dividend
IDR 5
Ex-dividend date
Jun 4, 2026
P/E ratio
8.73
52-wk high
IDR 1,600
52-wk low
IDR 680
EPS
IDR 80
Shares outstanding
46.88B
No. of employees
13K
Open
IDR 705
High
IDR 710
Low
IDR 690
Mkt. cap
32.54T
Avg. vol.
66.07M
Volume
53.01M
Dividend
2.88%
Quarterly dividend
IDR 5
Ex-dividend date
Jun 4, 2026
P/E ratio
8.73
52-wk high
IDR 1,600
52-wk low
IDR 680
EPS
IDR 80
Shares outstanding
46.88B
No. of employees
13K
News stories
From sources across the web
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT
CEO-
Employees12.9K
FoundedSep 10, 1966
Headquarters-
SectorPharmaceutical industry
Websitekalbe.co.id
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (IDR)
IDR 22.74 / IDR 20.91
+8.75%beat
Revenue / Est. (IDR)
9.68T / 9.66T
+0.23%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in IDR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
8.23T
8.91T
9.34T
9.68T
Cost of goods sold
4.94T
5.46T
5.92T
6.02T
Cost of revenue
4.94T
5.46T
5.92T
6.02T
Research and development expenses
136.97B
98.31B
160.88B
113.14B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.10T
2.51T
1.95T
2.23T
Operating expense
2.24T
2.60T
2.14T
2.33T
Total operating expenses
7.17T
8.06T
8.05T
8.36T
Operating income
1.06T
851.77B
1.28T
1.32T
Other non operating income
-3.97B
-3.78B
-4.17B
-3.63B
EBT including unusual items
1.19T
877.87B
1.30T
1.36T
EBT excluding unusual items
1.11T
888.55B
1.30T
1.36T
Income tax expense
275.47B
211.19B
252.81B
303.84B
Effective tax rate
23.09%
24.06%
19.41%
22.40%
Other operating expenses
4.75B
-7.23B
31.35B
-10.02B
Net income
898.17B
656.41B
1.03T
1.03T
Net profit margin
10.91%
7.37%
11.07%
10.63%
Earnings per share
19.78
14.44
22.72
22.74
Interest and investment income
47.01B
41.31B
40.43B
32.07B
Interest expense
-10.38B
-9.69B
-5.77B
-4.61B
Net interest expenses
36.63B
31.62B
34.66B
27.46B
Depreciation and amortization charges
-
-
-
-
EBITDA
1.26T
1.05T
1.47T
1.51T
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer